Literature DB >> 32427989

Mdm4 supports DNA replication in a p53-independent fashion.

Kai Wohlberedt1, Ina Klusmann1, Polina K Derevyanko1, Kester Henningsen1, Josephine Ann Mun Yee Choo1, Valentina Manzini1, Anna Magerhans1, Celeste Giansanti1, Christine M Eischen2, Aart G Jochemsen3, Matthias Dobbelstein4.   

Abstract

The Mdm4 (alias MdmX) oncoprotein, like its paralogue and interaction partner Mdm2, antagonizes the tumor suppressor p53. p53-independent roles of the Mdm proteins are emerging, and we have reported the ability of Mdm2 to modify chromatin and to support DNA replication by suppressing the formation of R-loops (DNA/RNA-hybrids). We show here that the depletion of Mdm4 in p53-deficient cells compromises DNA replication fork progression as well. Among various deletion mutants, only full-length Mdm4 was able to support DNA replication fork progression. Co-depletion of Mdm4 and Mdm2 further impaired DNA replication, and the overexpression of each partially compensated for the other's loss. Despite impairing replication, Mdm4 depletion only marginally hindered cell proliferation, likely due to compensation through increased firing of replication origins. However, depleting Mdm4 sensitized p53-/- cells to the nucleoside analog gemcitabine, raising the future perspective of using Mdm4 inhibitors as chemosensitizers. Mechanistically, Mdm4 interacts with members of the Polycomb Repressor Complexes and supports the ubiquitination of H2A, thereby preventing the accumulation of DNA/RNA-hybrids. Thus, in analogy to previously reported activities of Mdm2, Mdm4 enables unperturbed DNA replication through the avoidance of R-loops.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32427989      PMCID: PMC7521021          DOI: 10.1038/s41388-020-1325-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  The E2F-1 transcription factor is negatively regulated by its interaction with the MDMX protein.

Authors:  Gordon D Strachan; Kelly L Jordan-Sciutto; Ravikumar Rallapalli; Rocky S Tuan; David J Hall
Journal:  J Cell Biochem       Date:  2003-02-15       Impact factor: 4.429

2.  MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.

Authors:  Yetao Jin; Shelya X Zeng; Xiao-Xin Sun; Hunjoo Lee; Christine Blattner; Zhixiong Xiao; Hua Lu
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

Review 3.  High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.

Authors:  Xin Han; L Jeffrey Medeiros; Yu Helen Zhang; M James You; Michael Andreeff; Marina Konopleva; Carlos E Bueso-Ramos
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-04-01

4.  Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair.

Authors:  Jodi R Alt; Alyssa Bouska; Mario R Fernandez; Ronald L Cerny; Hua Xiao; Christine M Eischen
Journal:  J Biol Chem       Date:  2005-02-25       Impact factor: 5.157

5.  MDMX exerts its oncogenic activity via suppression of retinoblastoma protein.

Authors:  H Zhang; L Hu; W Qiu; T Deng; Y Zhang; J Bergholz; Z-X Xiao
Journal:  Oncogene       Date:  2015-02-23       Impact factor: 9.867

6.  Inactivation of the p53 pathway in retinoblastoma.

Authors:  Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

Review 7.  MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Authors:  Zdenka Matijasevic; Anna Krzywicka-Racka; Greenfield Sluder; Stephen N Jones
Journal:  Cell Cycle       Date:  2008-10-15       Impact factor: 4.534

8.  Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.

Authors:  Davide Danovi; Erik Meulmeester; Diego Pasini; Domenico Migliorini; Maria Capra; Ruth Frenk; Petra de Graaf; Sarah Francoz; Patrizia Gasparini; Alberto Gobbi; Kristian Helin; Pier Giuseppe Pelicci; Aart G Jochemsen; Jean-Christophe Marine
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

9.  HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.

Authors:  Laëtitia K Linares; Arnd Hengstermann; Aaron Ciechanover; Stefan Müller; Martin Scheffner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-24       Impact factor: 11.205

10.  MDM4 is a key therapeutic target in cutaneous melanoma.

Authors:  Agnieszka Gembarska; Flavie Luciani; Clare Fedele; Elisabeth A Russell; Michael Dewaele; Stéphanie Villar; Aleksandra Zwolinska; Sue Haupt; Job de Lange; Dana Yip; James Goydos; Jody J Haigh; Ygal Haupt; Lionel Larue; Aart Jochemsen; Hubing Shi; Gatien Moriceau; Roger S Lo; Ghanem Ghanem; Mark Shackleton; Federico Bernal; Jean-Christophe Marine
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

View more
  3 in total

1.  Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status.

Authors:  Javier Octavio Mejía-Hernández; Dinesh Raghu; Franco Caramia; Nicholas Clemons; Kenji Fujihara; Thomas Riseborough; Amina Teunisse; Aart G Jochemsen; Lars Abrahmsén; Giovanni Blandino; Andrea Russo; Cristina Gamell; Stephen B Fox; Catherine Mitchell; Elena A Takano; David Byrne; Panimaya Jeffreena Miranda; Reem Saleh; Heather Thorne; Shahneen Sandhu; Scott G Williams; Simon P Keam; Ygal Haupt; Sue Haupt
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

2.  Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.

Authors:  Viola Ellison; George K Annor; Clara Freedman; Gu Xiao; Devon Lundine; Elzbieta Freulich; Carol Prives; Jill Bargonetti
Journal:  Oncotarget       Date:  2021-06-08

3.  MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters.

Authors:  Kester Mo Henningsen; Valentina Manzini; Anna Magerhans; Sabrina Gerber; Matthias Dobbelstein
Journal:  Biomolecules       Date:  2021-12-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.